|Bid||21.99 x 1000|
|Ask||22.49 x 100|
|Day's range||21.00 - 22.05|
|52-week range||3.12 - 22.86|
|PE ratio (TTM)||N/A|
|Earnings date||8 Aug 2018 - 13 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||18.50|
On July 6, BioLife Solutions (BLFS) stock closed at $17.02, ~508% higher than its 52-week low of $2.80 on July 7, 2017. After BioLife’s July 2 announcement of its Q2 2018 results, its stock rose ~31.38% to $14.99 from $11.41 the day before. On July 3, the stock rose ~11.41% to close at $16.70. Last Friday, BioLife stock rose ~49% week-over-week to $17.02 from $11.41.
On July 2, BioLife Solutions released its preliminary revenue numbers for the second quarter. BioLife Solutions’ management increased its fiscal 2018 revenue guidance to $18.5 million–$20.0 million compared to its prior guidance of $14.5 million–$15.5 million.
BioLife Solutions’ (BLFS) biopreservation portfolio includes: hypothermic storage and cryopreservation freeze media products blood stem cell freezing products custom product formulation and custom packaging services contract aseptic manufacturing formulation, fill and finish of liquid media products Target market
BioLife Solutions (BLFS) is focused on bringing to market clinical grade cell and tissue hypothermic storage and cryopreservation freeze media. Its product platforms cater primarily to the biobanking, drug discovery, and regenerative medicine markets.
The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx
Zacks.com featured highlights: H&E Equipment Services, Nomad Foods, Strayer Education, BioLife Solutions and Assembly Biosciences